Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents (Q44601354)

4 December 2017

title

Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents (English)

1 reference

4 December 2017

1 reference

Theeten H

1 reference

4 December 2017

Van Damme P

1 reference

4 December 2017

Hoppenbrouwers K

1 reference

4 December 2017

Vandermeulen C

1 reference

4 December 2017

Leback E

1 reference

4 December 2017

Sokal EM

1 reference

4 December 2017

Wolter J

1 reference

4 December 2017

Schuerman L

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

4 December 2017

1 reference

4 December 2017

1 reference

4 December 2017

1 reference

4 December 2017

page(s)

1515-1521

1 reference

Adult immunization with acellular pertussis vaccine

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Acellular pertussis vaccines. Towards an improved safety profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Pertussis is a frequent cause of prolonged cough illness in adults and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Pertussis of adults and infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Mechanisms of stimulation of the immune response by aluminum adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Adjuvants--a classification and review of their modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Adjuvants--a balance between toxicity and adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Adjuvants for human vaccines--current status, problems and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Adverse reactions after injection of adsorbed diphtheria-pertussis-tetanus (DPT) vaccine are not due only to pertussis organisms or pertussis components in the vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Aluminum salts in vaccines--US perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Overview of vaccine adjuvants: present and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

The global impact of vaccines containing aluminium adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

The role of aluminium for adverse reactions and immunogenicity of diphtheria-tetanus booster vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Booster vaccination against diphtheria and tetanus in man. Comparison of three different vaccine formulations--III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Immunoglobulin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions and aluminium content of the vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Immunoglobulin E and G responses to pertussis toxin in children immunised with adsorbed and non-adsorbed whole cell pertussis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

The effect of adsorption with aluminium hydroxide on the reactogenicity of pertussis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Lack of consistent relationship between quantity of aluminum in diphtheria-tetanus-acellular pertussis vaccines and rates of extensive swelling reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Aluminum toxicokinetics regarding infant diet and vaccinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.002

10.1016/J.VACCINE.2004.08.002

7 January 2021

Identifiers

DOI

1 reference

4 December 2017

1 reference